go back

Brexucabtagene Autoleucel (Tecartus) CAR-T Therapy

Hawaii rates for HCPCS Q2053

Brexucabtagene autoleucel, up to 200 million autologous anti-CD19 CAR positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Rates data updated July 2026.

Professionalmedian $489,779 · 10th–90th $467,735$524,8070%50%10th90th$489,779$1.0K$5.0K$20.0K$100.0K$500.0K$2.0M

Distribution of negotiated rates across all payers (price axis is log-scale). Facility and professional rates are different services and are charted separately. Need provider-level prices? Contact us.

Insurance Carrier
Aetna
Setting
Professional
Modifier
Global
Typical Low
$489,778.82
Median
$489,778.82
Typical High
$512,861.38
Cigna
Setting
Professional
Modifier
Global
Typical Low
$489,778.82
Median
$489,778.82
Typical High
$588,843.66
HMSA
Setting
Professional
Modifier
Global
Typical Low
$467,735.14
Median
$467,735.14
Typical High
$467,735.14
Kaiser Permanente
Setting
Professional
Modifier
Global
Typical Low
$489,778.82
Median
$588,843.66
Typical High
$741,310.24
United
Setting
Professional
Modifier
Global
Typical Low
$89,125.09
Median
$436,515.83
Typical High
$3,467,368.50